Related Experiment Videos
Unaltered insulin sensitivity during calcium channel blockade with amlodipine
P Ferrari1, D Giachino, P Weidmann
1Medizinische Poliklinik, University of Berne, Switzerland.
European Journal of Clinical Pharmacology
|January 1, 1991
Summary
Amlodipine, a calcium channel blocker, did not affect insulin sensitivity or glucose levels in healthy men. This study found no significant changes in insulin secretion or lipid profiles during amlodipine treatment.
Area of Science:
- Endocrinology
- Cardiovascular Pharmacology
- Metabolic Research
Background:
- Insulin sensitivity (SI) is crucial in metabolic and cardiovascular health.
- Cardiovascular disorders often involve impaired insulin sensitivity.
- Calcium channel blockers (CCBs) are common cardiovascular drugs.
Purpose of the Study:
- To investigate the impact of amlodipine, a CCB, on insulin sensitivity.
- To assess amlodipine's effects on glucose homeostasis and lipid profiles.
- To evaluate potential therapeutic or prognostic relevance of CCBs in metabolic regulation.
Main Methods:
- A randomized, placebo-controlled study in 38 healthy young men.
- Insulin sensitivity assessed using the Minimal Model Method.
- Measurements included fasting glucose, insulin, triglycerides, and lipoprotein cholesterol fractions.
- Amlodipine 5 mg daily was administered for 3 weeks.
Main Results:
- Amlodipine significantly reduced systolic blood pressure compared to placebo.
- No significant changes were observed in insulin sensitivity (SI).
- Fasting glucose, insulin levels, and lipid profiles remained unaltered.
Conclusions:
- Amlodipine treatment did not alter insulin sensitivity or secretion in healthy young men.
- The drug did not significantly impact glucose homeostasis or lipid regulation.
- These findings suggest CCB therapy with amlodipine may not adversely affect metabolic parameters in this population.